These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25851904)

  • 21. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
    Chen RL; Reynolds CP; Seeger RC
    Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2.
    Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee MB
    J Immunother; 1998 Jan; 21(1):75-83. PubMed ID: 9456440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
    Lin CC; Shen YC; Chuang CK; Liao SK
    Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
    Kushner BH; Cheung NK
    Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.
    Occhino M; Raffaghello L; Burrone O; Gambini C; Pistoia V; Corrias MV; Bestagno M
    Int J Mol Med; 2004 Sep; 14(3):383-8. PubMed ID: 15289889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
    Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
    Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
    Saito M; Yu RK; Cheung NK
    Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody.
    Hu J; Huang X; Ling CC; Bundle DR; Cheung NK
    J Immunol; 2009 Nov; 183(9):5748-55. PubMed ID: 19812201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
    Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
    Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
    Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
    Honsik CJ; Jung G; Reisfeld RA
    Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
    Nakamura K; Tanaka Y; Shitara K; Hanai N
    Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization.
    Lunn MP; Johnson LA; Fromholt SE; Itonori S; Huang J; Vyas AA; Hildreth JE; Griffin JW; Schnaar RL; Sheikh KA
    J Neurochem; 2000 Jul; 75(1):404-12. PubMed ID: 10854286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.